Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

2 approaches to diagnosing heparin-induced thrombocytopenia

Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

Key clinical point: The HEP and 4Ts scores had similar operative characteristics for diagnosing heparin-induced thrombocytopenia.

Major finding: The area under the ROC curves for the HEP Score and 4Ts Score were similar (0.81 vs. 0.76; P = .121).

Study details: A prospective study of 292 adults with suspected acute HIT who were hospitalized at the University of Pennsylvania or affiliated community hospitals.

Disclosures: The National Institutes of Health funded the study. Dr. Pishko reported having no financial disclosures.

Source: Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103.

Citation:

Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Must Reads in Thrombosis

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Emapalumab for primary hemophagocytic lymphohistiocytosis, Locatelli F et al. ASH 2018; Abstract LBA-6

Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4

Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09